Effect of Eprosartan and Enalapril in the Treatment of Black Hypertensive Patients: Subgroup Analysis of a 26-week, Double-blind, Multicentre Study

References

• National High Blood Pressure Education Program Working Group. 1993 National High Blood Pressure Education Program Working Group on primary prevention of hypertension. Arch. Intern. Med., 153: 186–2081. National High Blood Pressure Education Program Working Group. 1993 National High Blood Pressure Education Program Working Group on primary prevention of hypertension. Arch. Intern. Med., 153: 186–208
   PubMed Web of Science ®Google Scholar
• Lackland D. T., Keil J. E. Epidemiology of hypertension in African Americans. Semin. Nephrol. 1996; 16: 63–702. Lackland D. T., Keil J. E. Epidemiology of hypertension in African Americans. Semin. Nephrol. 1996; 16: 63–70
   PubMed Web of Science ®Google Scholar
• Kenton E. J., III. Diagnosis and treatment of concomitant hypertension and stroke. J. Natl. Med. Assoc. 1996; 88: 364–3683. Kenton E. J., III. Diagnosis and treatment of concomitant hypertension and stroke. J. Natl. Med. Assoc. 1996; 88: 364–368
   PubMed Web of Science ®Google Scholar
• Walker W. G. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am. J. Kidney. Dis. 1993; 22: 164–1734. Walker W. G. Hypertension-related renal injury: a major contributor to end-stage renal disease. Am. J. Kidney. Dis. 1993; 22: 164–173
   PubMed Web of Science ®Google Scholar
• Weinberger M. H. Hypertension in African Americans: The role of sodium chloride and extracellular fluid volume. Semin. Nephrol. 1996; 16: 110–1165. Weinberger M. H. Hypertension in African Americans: The role of sodium chloride and extracellular fluid volume. Semin. Nephrol. 1996; 16: 110–116
   PubMed Web of Science ®Google Scholar
• Williams G. H. Converting enzyme inhibitors in the treatment of hypertension. N. Engl. J. Med. 1988; 319: 1517–15256. Williams G. H. Converting enzyme inhibitors in the treatment of hypertension. N. Engl. J. Med. 1988; 319: 1517–1525
   PubMed Web of Science ®Google Scholar
• Materson B. J., Reda D. J., Cushman W. C., et al. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. N. Engl. J. Med. 1993; 328: 914–9217. Materson B. J., Reda D. J., Cushman W. C., et al. Single-drug therapy for hypertension in men: A comparison of six antihypertensive agents with placebo. N. Engl. J. Med. 1993; 328: 914–921
   PubMed Web of Science ®Google Scholar
• Campese V. M., Parise M., Karubin F., Bigazzi R. Abnormal renal hemodynamics in black salt sensitive patients with hypertension. Hypertension 1991; 18: 805–8218. Campese V. M., Parise M., Karubin F., Bigazzi R. Abnormal renal hemodynamics in black salt sensitive patients with hypertension. Hypertension 1991; 18: 805–821
   PubMed Web of Science ®Google Scholar
• Hall W. D. Pathophysiology of hypertension in blacks. Am. J. Hypertens. 1990; 3: 366S–371S9. Hall W. D. Pathophysiology of hypertension in blacks. Am. J. Hypertens. 1990; 3: 366S–371S
   Web of Science ®Google Scholar
• Weir M. R., Gray J. M., Pater R., Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients: The Trandolapril Multicenter Study Group. Hypertension 1995; 26: 124–13010. Weir M. R., Gray J. M., Pater R., Saunders E. Differing mechanisms of action of angiotensin-converting enzyme inhibition in black and white hypertensive patients: The Trandolapril Multicenter Study Group. Hypertension 1995; 26: 124–130
   PubMed Web of Science ®Google Scholar
• Saunders E., Weir M. R., Kong B. W., et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch. Intern. Med. 1990; 150: 1707–171311. Saunders E., Weir M. R., Kong B. W., et al. A comparison of the efficacy and safety of a beta-blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive blacks. Arch. Intern. Med. 1990; 150: 1707–1713
   PubMed Web of Science ®Google Scholar
• Nishimura I. I., Hoffman S., Baltatu O., Sugimura K., Ganten D., Urata H. Angiotensin-I-converting-enzyme and chymase in cardiovascular tissues. Kidney Int. 1996; 49: S18–S23, Suppl12. Nishimura I. I., Hoffman S., Baltatu O., Sugimura K., Ganten D., Urata H. Angiotensin-I-converting-enzyme and chymase in cardiovascular tissues. Kidney Int. 1996; 49: S18–S23, Suppl
   Google Scholar
• Hollenberg N. K., Fisher N. D. L. Renal circulation and blockade of the renin-angiotensin system. Hypertension 1995; 26: 602–60913. Hollenberg N. K., Fisher N. D. L. Renal circulation and blockade of the renin-angiotensin system. Hypertension 1995; 26: 602–609
   PubMed Web of Science ®Google Scholar
• Burnier M., Buclin T., Biollaz B., Nussberger J., Waeber B., Brunner H. R. Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers. Kidney Int. 1996; 49: S24–S29, Suppl14. Burnier M., Buclin T., Biollaz B., Nussberger J., Waeber B., Brunner H. R. Pharmacokinetic-pharmacodynamic relationships of three angiotensin II receptor antagonists in normal volunteers. Kidney Int. 1996; 49: S24–S29, Suppl
   Google Scholar
• Elliott W. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. J. Hum. Hypertens. 1999, in press15. Elliott W. Double-blind comparison of eprosartan and enalapril on cough and blood pressure in unselected hypertensive patients. J. Hum. Hypertens. 1999, in press
   PubMedGoogle Scholar
• Hedner T., Himmelmann A. The efficacy and tolerance of once- and twice-daily eprosartan in essential hypertension. J. Hypertens. 1998, in press16. Hedner T., Himmelmann A. The efficacy and tolerance of once- and twice-daily eprosartan in essential hypertension. J. Hypertens. 1998, in press
   Web of Science ®Google Scholar
• Dunn F. G., Oigman W., Ventura H. O., Messerli F. H., Kobrin I., Frohlich E. D. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am. J. Cardiol 1984; 53: 105–10817. Dunn F. G., Oigman W., Ventura H. O., Messerli F. H., Kobrin I., Frohlich E. D. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am. J. Cardiol 1984; 53: 105–108
   PubMed Web of Science ®Google Scholar
• Maki D. D., Ma J. Z., Louis T. A., Kasiske B. L. Effects of antihypertensive agents on the kidney. Arch: Int. Med. 1995; 155: 1073–108218. Maki D. D., Ma J. Z., Louis T. A., Kasiske B. L. Effects of antihypertensive agents on the kidney. Arch: Int. Med. 1995; 155: 1073–1082
   PubMed Web of Science ®Google Scholar
• Israili Z. H., Hall W. D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann. Intern. Med. 1992; 117: 234–24219. Israili Z. H., Hall W. D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy: a review of the literature and pathophysiology. Ann. Intern. Med. 1992; 117: 234–242
   PubMed Web of Science ®Google Scholar
• Kreft-Jais C., Laforest L., Bonnardeaux A., Dumont C., Plouin P-F., Jeunemaitre X. ACE inhibitors, cough, and genetics. Lancet (letter) 1994; 343: 74020. Kreft-Jais C., Laforest L., Bonnardeaux A., Dumont C., Plouin P-F., Jeunemaitre X. ACE inhibitors, cough, and genetics. Lancet (letter) 1994; 343: 740
   PubMedGoogle Scholar